Full Text:


Ǵм Yeungnam Univ J Med 2018;35(1):1-6


Beta-amyloid imaging in dementia

Kyung Ah Chun
Department of Nuclear Medicine, Yeungnam University College of Medicine, Daegu, Korea
Corresponding Author: Kyung Ah Chun, Department of Nuclear Medicine, Yeungnam University College of Medicine, 170, Hyeonchung-ro, Nam-gu, Daegu 42415, Korea
Tel: +82-53-620-3135, Fax: +82-53-620-3135
E-mail: cka52@yumail.ac.kr

Received: October 22, 2017, Revised: November 30, 2017 Accepted: January 3, 2018


Alzheimer's disease (AD) is a neurodegenerative disorder associated with extracellular plaques, composed of amyloid-beta (A), in the brain. Although the precise mechanism underlying the neurotoxicity of A has not been established, A accumulation is the primary event in a cascade of events that lead to neurofibrillary degeneration and dementia. In particular, the A burden, as assessed by neuroimaging, has proved to be an excellent predictive biomarker. Positron emission tomography, using ligands such as 11C-labeled Pittsburgh Compound B or 18F-labeled tracers, such as 18F-florbetaben, 18F-florbetapir, and 18F-flutemetamol, which bind to A deposits in the brain, has been a valuable technique for visualizing and quantifying the deposition of A throughout the brain in living subjects. A imaging has very high sensitivity for detecting AD pathology. In addition, it can predict the progression from mild cognitive impairment to AD, and contribute to the development of disease-specific therapies.

Key Words: Keywords: Alzheimers disease; Amyloid-beta; Positron emission tomography